About Us

About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Geron (NASDAQ: GERN) Reports Positive Results From IMerge Phase 3 Trial of Imetelstat for Lower Risk MDS

By: Spotlight Growth

Geron Corporation (NASDAQ: GERN) is engaged as a late-stage biopharmaceutical company, which is focused on the research and development of treatments for patients suffering from hematologic malignancies. Shares of the late-stage biopharma company are rallying 37% through early trading on Wednesday, January 4, 2023. Over the past three months, Geron has seen average daily volume of 3.99 million shares. However, volume of 94.41 million shares or dollar volume of around $311.55 million, has already exchanged hands through early trading.

Shares of Geron are gaining after the company reported positive top-line and secondary endpoint results from its IMerge Phase 3 clinical trial of Imetelstat for the treatment of lower risk myelodysplastic syndromes (MDS) who have relapsed, refractory or are not eligible for erythropoiesis stimulating agents (ESAs).

The IMerge Phase 3 trial was a double-blind, 2:1 randomized, placebo-controlled clinical trial. During the trial’s first 8 weeks, patients treated with Imetelstat saw very statistically significant improvements compared to the placebo group. After eight weeks, Imetelstat patients saw a transfusion independence (TI) reading of 47 compared to 9 in the placebo group. This met the primary endpoints for the Phase 3 trial. Over a 24-week period, Imetelstat patients saw a TI reading of 33, compared to the placebo group’s 2 result.

This shows that Imetelstat-treated patients were able to achieve transfusion independent broadly among lower risk MDS subtypes. Average hemoglobin levels in Imetelstat patients saw a robust increase over time compared to the placebo group. In additional, test groups saw clinically-meaningful average reduction in RBC transfusion units compared to the placebo group.

Imetelstat maintained a very strong safety profile throughout the clinical trial. Treatment emergent adverse events (TEAEs) that were seen in the IMerge Phase 3 trial were consistent with the known potential safety risks of the treatment. No new safety issues were found.

Moving forward, Geron Corporation says it plans to submit a New Drug Application with the U.S. Food and Drug Administration, as well as a Marketing Authorization Application (MAA) with EU regulators during the second half of 2023. Geron estimates commcerical launch of Imetelstat to take place sometime during the first half of 2024 in the U.S. and by the end of 2024 in the EU.

“Today is a great day for lower risk MDS patients who are living with the burden of transfusions. The results from the IMerge Phase 3 study were resoundingly positive, presenting compelling durability of transfusion independence, delivering on the promise of imetelstat and telomerase inhibition for these patients,” said John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer. “This milestone is the first of many upcoming catalysts for Geron, with planned U.S. and EU regulatory submissions in 2023, as well as preparations for a potential U.S. commercial launch. In addition, in 2024, we expect an interim analysis of the IMpactMF Phase 3 trial of imetelstat in relapsed/refractory myelofibrosis.”

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post Geron (NASDAQ: GERN) Reports Positive Results From IMerge Phase 3 Trial of Imetelstat for Lower Risk MDS appeared first on Spotlight Growth.

More News

View More
New Catalysts Build Positive Pressure on Intel Stock
Via MarketBeat
Topics Artificial Intelligence
Tickers ARM INTC TSLA TSM
Bloom Energy Booms on AI Power Demand and Analyst Upgrades
Via MarketBeat
Topics Artificial Intelligence
Tickers AEP AMZN BE MS ORCL
Can Apple’s iPhone 17 and AI Push Its Stock to New Highs?
Via MarketBeat
Topics Artificial Intelligence
Tickers AAPL
Oracle to Hit $1 Trillion Valuation in 2025: Here’s Why
Via MarketBeat
Topics Artificial Intelligence
Tickers AMZN CRM GOOGL META MSFT ORCL
General Mills Is a Generational Opportunity for Income Investors
Via MarketBeat
Tickers GIS
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.